Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that a poster examining the effects of TONMYA(R) (cyclobenzaprine HCl sublingual tablets) on fibromyalgia symptoms and physical function will be presented at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, scheduled for Oct. 26-30, 2026, in Bangkok, Thailand. The presentation marks a significant milestone for the company and for patients, as TONMYA is the first new treatment for fibromyalgia in more than 15 years, according to the company's press release.
TONMYA received U.S. Food and Drug Administration approval on Aug. 15, 2025, and was commercially launched in the United States on Nov. 17, 2025. The upcoming poster will showcase data on how the sublingual tablet affects fibromyalgia symptoms and physical function, potentially reinforcing its clinical profile and supporting broader adoption among healthcare providers. For investors, the presentation at a major international pain conference could raise awareness and credibility for TONMYA, which is Tonix's flagship medicine.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's CNS commercial infrastructure supports its marketed products, including acute migraine products Zembrace(R) SymTouch(R) and Tosymra(R). Tonix is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Additionally, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
The IASP World Congress on Pain is a global gathering of pain researchers and clinicians, and presenting data there can enhance Tonix's visibility and validate its research efforts. The news was disseminated through TinyGems, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN, which provides corporate communications solutions and reaches a wide audience through social media distribution. For more details, refer to the full press release at https://ibn.fm/jFHh3. Investors can also find the latest news and updates relating to TNXP in the company's newsroom at https://ibn.fm/TNXP.
